Table 4

Five-year EFS in subgroups with 10 or more patients according to the result of randomization

CharacteristicsRandomized to GO EFS, %Randomized to no further therapy EFS, %P
Sex    
    Male 42 46 .5 
    Female 68 57 .5 
Age, y    
    0-1 74 80 .8 
    2-9 51 36 .3 
    10+ 42 50 .3 
White blood count, × 109/L    
    0-9.9 44 47 .7 
    10+ 61 53 .7 
FAB classification    
    M1/M2 28 32 .5 
    M4/M5 70 71 .8 
Cytogenetics    
    Normal karyotype 53 44 .4 
    t(8;21) or inv(16) 38 50 .9 
    11q23 68 62 .9 
    Other aberrations 59 49 .9 
Remission achieved    
    After first induction 66 59 .7 
    After second induction 11 17 .4 
CharacteristicsRandomized to GO EFS, %Randomized to no further therapy EFS, %P
Sex    
    Male 42 46 .5 
    Female 68 57 .5 
Age, y    
    0-1 74 80 .8 
    2-9 51 36 .3 
    10+ 42 50 .3 
White blood count, × 109/L    
    0-9.9 44 47 .7 
    10+ 61 53 .7 
FAB classification    
    M1/M2 28 32 .5 
    M4/M5 70 71 .8 
Cytogenetics    
    Normal karyotype 53 44 .4 
    t(8;21) or inv(16) 38 50 .9 
    11q23 68 62 .9 
    Other aberrations 59 49 .9 
Remission achieved    
    After first induction 66 59 .7 
    After second induction 11 17 .4 

GO indicates gemtuzumab ozogamicin; EFS, event-free survival; and FAB, French-American-British.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal